Literature DB >> 22014047

Clinicopathological analysis of the age-related differences in patients with Epstein-Barr virus (EBV)-associated extranasal natural killer (NK)/T-cell lymphoma with reference to the relationship with aggressive NK cell leukaemia and chronic active EBV infection-associated lymphoproliferative disorders.

Emiko Takahashi1, Koichi Ohshima, Hiroshi Kimura, Kazuo Hara, Ritsuro Suzuki, Keisei Kawa, Tadaaki Eimoto, Shigeo Nakamura.   

Abstract

AIMS: Extranodal natural killer (NK)/T-cell lymphoma (NKTL), comprising nasal NKTL and extranasal NKTL (ENKTL), is associated with Epstein-Barr virus (EBV). A bimodal age distribution was noted in NKTL patients. We examined the clinicopathological differences between two age groups of ENKTL patients (n = 23) and compared the findings with those of aggressive NK cell leukaemia (ANKL; n = 10) and monoclonal chronic active EBV infection-associated T/NK-cell lymphoproliferative disorders [chronic active EBV infection/TNK-lymphoproliferative disorders (CAEBV/TNK-LPD)] of NK-cell type (n = 45). METHODS AND
RESULTS: Distinct differences existed between elderly (> 50 years; n = 13) and younger (≤ 50 years; n = 10) ENKTL patients; the latter showed a higher disease stage (P = 0.0286), worse performance status (P = 0.0244), more frequent B symptoms (P = 0.0286) and more frequent liver, spleen and bone marrow involvement (P = 0.0222, 0.0005 and 0.0259, respectively). Few clinicopathological differences existed between younger ENKTL and ANKL patients. Patients with monoclonal CAEBV/TNK-LPD of NK-cell type (n = 45) showed features similar to those in younger ENKTL/ANKL patients, except a more juvenile onset of CAEBV-related symptoms and better prognosis. However, the onset age of overt leukaemia/lymphoma in CAEBV/TNK-LPD patients and overall survival thereafter were similar to those in younger ENKTL/ANKL patients.
CONCLUSIONS: ENKTL (≤ 50 years) is distinct from that in elderly patients and may encompass ANKL and overlap in the clinicopathological profile with NK-cell type CAEBV/TNK-LPD. 2011 Blackwell Publishing Limited.

Entities:  

Mesh:

Year:  2011        PMID: 22014047     DOI: 10.1111/j.1365-2559.2011.03976.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  14 in total

Review 1.  Extranodal NK/T-cell lymphoma, nasal type: a case report of 7-year natural course and review of literature.

Authors:  Juan Du; Pan-Pan Ma; Qun-Ying Wang; Chun-Xiao Chen; Jun Li
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

Review 2.  Emerging insights on the pathogenesis and treatment of extranodal NK/T cell lymphomas (ENKTL).

Authors:  Bradley M Haverkos; Carrie Coleman; Alejandro A Gru; Zenggang Pan; Jonathan Brammer; Rosemary Rochford; Anjali Mishra; Christopher C Oakes; Robert A Baiocchi; Aharon G Freud; Pierluigi Porcu
Journal:  Discov Med       Date:  2017-03       Impact factor: 2.970

3.  LMP1 and LMP2A are potential prognostic markers of extranodal NK/T-cell lymphoma, nasal type (ENKTL).

Authors:  Yuan Mao; Da-Wei Zhang; Huijun Zhu; Hong Lin; Lin Xiong; Qing Cao; Ying Liu; Qing-Dong Li; Jia-Ren Xu; Lin-Feng Xu; Ren-Jie Chen
Journal:  Diagn Pathol       Date:  2012-12-13       Impact factor: 2.644

4.  CD30+ extranodal natural killer/T-cell lymphoma mimicking phlegmonous myositis: A case report.

Authors:  Yan-Jia Yang; Ya-Xin Li; Yan-Bin Liu; Mei Yang; Kai Liu
Journal:  Oncol Lett       Date:  2014-02-28       Impact factor: 2.967

Review 5.  Clinical Features, Pathogenesis, and Treatment of Large Granular Lymphocyte Leukemias.

Authors:  Kazuo Oshimi
Journal:  Intern Med       Date:  2017-07-15       Impact factor: 1.271

6.  Aggressive NK-cell leukemia: clinical subtypes, molecular features, and treatment outcomes.

Authors:  Y-T Tang; D Wang; H Luo; M Xiao; H-S Zhou; D Liu; S-P Ling; N Wang; X-L Hu; Y Luo; X Mao; Q-L Ao; J Huang; W Zhang; L-S Sheng; L-J Zhu; Z Shang; L-L Gao; P-L Zhang; M Zhou; K-G Zhou; L-G Qiu; Q-F Liu; H-Y Zhang; J-Y Li; J Jin; L Fu; W-L Zhao; J-P Chen; X Du; G Huang; Q-F Wang; J-F Zhou; L Huang
Journal:  Blood Cancer J       Date:  2017-12-21       Impact factor: 11.037

Review 7.  Nodal EBV+ cytotoxic T-cell lymphoma: A literature review based on the 2017 WHO classification.

Authors:  Seiichi Kato; Daisuke Yamashita; Shigeo Nakamura
Journal:  J Clin Exp Hematop       Date:  2020

8.  [Clinical analysis of 13 patients with EB virus-positive T-cell lymphoproliferative disorders in adults].

Authors:  P F Shi; Y P Xie; Y Xu; S X Qian; K Chen; D Q Gao; X L Huang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-03-14

9.  Prognostic significance of EBV latent membrane protein 1 expression in lymphomas: evidence from 15 studies.

Authors:  Yuan Mao; Mei Ping Lu; Hong Lin; Da Wei Zhang; Ying Liu; Qing Dong Li; Zhi Gang Lv; Jia Ren Xu; Ren Jie Chen; Jin Zhu
Journal:  PLoS One       Date:  2013-04-17       Impact factor: 3.240

10.  Prognostic impact of Epstein-Barr virus (EBV)-DNA copy number at diagnosis in chronic lymphocytic leukemia.

Authors:  Jin-Hua Liang; Rui Gao; Yi Xia; Robert Peter Gale; Rui-Ze Chen; Yu-Qiong Yang; Li Wang; Xiao-Yan Qu; Hai-Rong Qiu; Lei Cao; Min Hong; Rong Wang; Yan Wang; Lei Fan; Yao-Yu Chen; Zhi-Bin Hu; Jian-Yong Li; Wei Xu
Journal:  Oncotarget       Date:  2016-01-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.